iData Insights

Neuroblastoma - Pipeline Review, H2 2015 Now Available at iData Insights

Press Release   •   Jan 22, 2016 17:27 IST

Neuroblastoma - Pipeline Review, H2 2015 Summary Global Markets Direct s, Neuroblastoma - Pipeline Review, H2 2015 , provides an overview of the Neuroblastoma s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Neuroblastoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neuroblastoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Neuroblastoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Neuroblastoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Neuroblastoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Browsewith TOC @

To Get Sample Copy of Report visit @

Table of Contents

Introduction 9

Global Markets Direct Report Coverage 9

Neuroblastoma Overview 10

Therapeutics Development 11

Pipeline Products for Neuroblastoma - Overview 11

Pipeline Products for Neuroblastoma - Comparative Analysis 12

Neuroblastoma - Therapeutics under Development by Companies 13

Neuroblastoma - Therapeutics under Investigation by Universities/Institutes 18

Neuroblastoma - Pipeline Products Glance 21

Late Stage Products 21

Clinical Stage Products 22

Early Stage Products 23

Neuroblastoma - Products under Development by Companies 24

Neuroblastoma - Products under Investigation by Universities/Institutes 29

Neuroblastoma - Companies Involved in Therapeutics Development 31

Ability Pharma, SL 31

Acetylon Pharmaceuticals, Inc. 32

Advanced Accelerator Applications SA 33

Ampio Pharmaceuticals, Inc. 34

APEIRON Biologics AG 35

AstraZeneca Plc 36

ATLAB Pharma SAS 37

Bellicum Pharmaceuticals, Inc. 38

Bexion Pharmaceuticals, LLC. 39

BioLineRx, Ltd. 40

Bionucleon Srl 41

Biotec Pharmacon ASA 42

Cebiotex, S.L. 43

Celgene Corporation 44

Chugai Pharmaceutical Co., Ltd. 45

Cleveland BioLabs, Inc. 46

CureFAKtor Pharmaceuticals, LLC 47

Cyclacel Pharmaceuticals, Inc. 48

DEKK-TEC, Inc. 49

Errant Gene Therapeutics, LLC 50

F. Hoffmann-La Roche Ltd. 51

GlaxoSmithKline Plc 52

Ignyta, Inc. 53

Juno Therapeutics Inc. 54

Lindis Biotech GmbH 55

MabVax Therapeutics Holdings, Inc. 56

MEI Pharma, Inc. 57

Merck & Co., Inc. 58

Merrimack Pharmaceuticals, Inc. 59

Novartis AG 60

Novogen Limited 61

Pharmacyclics, Inc. 62

Pono Pharma 63

Progenics Pharmaceuticals, Inc. 64

Recombio S.L 65

Ribomic Inc. 66

Sareum Holdings Plc 67

Shionogi & Co., Ltd. 68

Sutro Biopharma, Inc. 69

Teva Pharmaceutical Industries Limited 70

Threshold Pharmaceuticals, Inc. 71

Neuroblastoma - Therapeutics Assessment 72

Assessment by Monotherapy Products 72

Assessment by Combination Products 73

Assessment by Target 74

Assessment by Mechanism of Action 78

Assessment by Route of Administration 82

Assessment by Molecule Type 84

Drug Profiles 86

1-B7 - Drug Profile 86

31-F9 - Drug Profile 87

abexinostat hydrochloride - Drug Profile 88

ABTL-0812 - Drug Profile 91

ACY-957 - Drug Profile 93

AMB-8LK - Drug Profile 94

AMXT-1501 + eflornithine hydrochloride - Drug Profile 95

Antisense RNAi Oligonucleotide for Oncology - Drug Profile 97

APN-301 - Drug Profile 98

APN-311 - Drug Profile 99

ATL-301 - Drug Profile 101

ATL-302 - Drug Profile 102

ATM-3507 - Drug Profile 103

AZ-64 - Drug Profile 104

BACPT-DP - Drug Profile 105

bevacizumab - Drug Profile 107

BL-8040 - Drug Profile 113

BN-210 - Drug Profile 115

BPX-701 - Drug Profile 116

BXQ-350 - Drug Profile 117

CCT-244747 - Drug Profile 119

CCT-245737 - Drug Profile 121

CCT-68127 - Drug Profile 123

CEB-01 - Drug Profile 124

Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile 125

Cellular Immunotherapy for Neuroblastoma - Drug Profile 127

Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile 128

Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile 129

Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile 130

celyvir - Drug Profile 131

CEP-28122 - Drug Profile 133

CFAKY-15 - Drug Profile 134

CG-1521 - Drug Profile 135

CSG-007 - Drug Profile 136

CVE-199 - Drug Profile 137

CYC-065 - Drug Profile 138

Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 139

Edotreotide Labeled Yttrium 90 - Drug Profile 140

eflornithine hydrochloride - Drug Profile 142

eh8B6 - Drug Profile 144

entrectinib - Drug Profile 145

evofosfamide - Drug Profile 147

firtecan pegol - Drug Profile 155

FSEC - Drug Profile 157

GSK-525762 - Drug Profile 158

iobenguane sulfate I 131 - Drug Profile 159

irinotecan hydrochloride - Drug Profile 161

JCAR-023 - Drug Profile 164

Lutathera - Drug Profile 165

M-606 - Drug Profile 168

M-7085 - Drug Profile 169

Monoclonal Antibody Conjugate to Target B7-H3 for Cancer - Drug Profile 170

Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile 171

Monoclonal Antibody to Target CD3 for Neuroblastoma - Drug Profile 172

Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma - Drug Profile 173

Monoclonal Antibody to Target GD2 and CD3 for Neuroblastoma and Melanoma - Drug Profile 175

Monoclonal Antibody to Target GD2 for Neuroblastoma - Drug Profile 176

NCE-001 - Drug Profile 177

Oncolytic Virus for Oncology - Drug Profile 178

P-937 - Drug Profile 179

paclitaxel albumin bound - Drug Profile 180

pazopanib hydrochloride - Drug Profile 184

pembrolizumab - Drug Profile 190

Peptide to Inhibit HDAC for Neuroblastoma - Drug Profile 199

pracinostat - Drug Profile 200

racotumomab - Drug Profile 202

RBM-001 - Drug Profile 204

Recombinant Protein to Inhibit HDAC for Neuroblastoma - Drug Profile 206

ribociclib - Drug Profile 207

RKS-262 - Drug Profile 210

RNAi Oligonucleotides for Neuroblastoma - Drug Profile 211

RSF-701 - Drug Profile 212

S-588410 - Drug Profile 213

SAR-020106 - Drug Profile 214

SAR-4 - Drug Profile 216

SF-1126 - Drug Profile 217

Small Molecules for Neuroblastoma - Drug Profile 219

Small Molecules for Neuroblastoma - Drug Profile 220

Small Molecules to Antagonize ALK for Oncology - Drug Profile 221

Soluble Beta Glucan - Drug Profile 222

SRX-2523 - Drug Profile 225

Syrbactins - Drug Profile 227

TL-118 - Drug Profile 228

TPI-287 - Drug Profile 230

TR-100 - Drug Profile 232

TRBS-07 - Drug Profile 233

Trilexium - Drug Profile 234

Vaccine 1 for Oncology - Drug Profile 235

Vaccine for Neuroblastoma - Drug Profile 236

Vaccine for Neuroblastoma - Drug Profile 238

Vaccine for Neuroblastoma - Drug Profile 239

X-396 - Drug Profile 240

Neuroblastoma - Recent Pipeline Updates 241

Neuroblastoma - Dormant Projects 319

Neuroblastoma - Discontinued Products 322

Neuroblastoma - Product Development Milestones 323

Featured News & Press Releases 323

Appendix 332

Methodology 332

Coverage 332

Secondary Research 332

Primary Research 332

Expert Panel Validation 332

Contact Us 332

Disclaimer 333"

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects